Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech
Phio Pharmaceuticals shares rose 1.39% to $1.095 Wednesday as the company prepared to present its PH-762 skin-cancer program at a virtual investor event. CEO Robert Bitterman will discuss the INTASYL platform and Phase 1b results, which showed a 65% response rate among cutaneous squamous cell carcinoma patients. Phio plans to seek FDA feedback on its next trial design in Q2 2026. Market cap stood near $12.55 million.